Displaying drugs 2326 - 2350 of 3779 in total
TAK-733
TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.
Investigational
MK-7622
MK-7622 has been used in trials studying the treatment of Alzheimer's Disease.
Investigational
MIV-711
Investigational
TAK-715
TAK-715 is under investigation in clinical trial NCT00760864 (Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis).
Investigational
SRA-737
Investigational
ALT-P7
Investigational
F6-734
F6-734 is a bispecific monoclonal antibody with affinity for anticarcinoembryonic antigen (CEA) and anti-diethylenetriamine pentaacetic acid (DTPA) (hMN-14 × m734).[A255217,A255222]
Investigational
INZ-701
INZ-701 is an enzyme replacement therapy under development with the intention to be used for the treatment of calcification disorders of the circulatory system, bones, and kidneys.
Investigational
TAK-754
TAK-754 is an adeno-associated virus serotype 8 vector (AAV8) expressing B domain deleted codon optimized factor VIII. Developed by Takeda, it is being investigated for the treatment of hemophilia A.
Investigational
JBI-778
Investigational
DMP-777
DMP-777 is a selective inhibitor of polymorphonuclear leukocyte (PMN) elastase.
Investigational
(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
Experimental
Matched Iupac: … (2R,6S,7R)-7-(4-hydroxyphenyl)-10-(methoxymethyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien …
PSN9301
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
BCX9250
Investigational
8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
Experimental
Matched Name: … 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine …
Matched Iupac: … 8-[(2,5-dimethoxyphenyl)methyl]-2-fluoro-9-(pent-4-yn-1-yl)-9H-purin-6-amine …
Matched Iupac: … 8-[(2,5-dimethoxyphenyl)methyl]-2-fluoro-9-(pent-4-yn-1-yl)-9H-purin-6-amine …
9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
Experimental
Matched Name: … 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine …
Matched Iupac: … 9-butyl-8-[(2,5-dimethoxyphenyl)methyl]-2-fluoro-9H-purin-6-amine …
Matched Iupac: … 9-butyl-8-[(2,5-dimethoxyphenyl)methyl]-2-fluoro-9H-purin-6-amine …
MIP-1095 I-123
123 I Mip 1095 is under investigation in clinical trial NCT00712829 (Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents).
Investigational
ANG1005
Investigational
CT103A
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
Anecortave acetate
Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is...
Investigational
Matched Iupac: … 2-[(1R,3aS,3bS,9aS,11aS)-1-hydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,11H,11aH-cyclopenta …
Deoxyinosine
Experimental
Matched Synonyms: … 9-(2-deoxy-β-D-erythro-pentofuranosyl)-9H-purin-6-ol …
Matched Iupac: … 9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-ol …
Matched Iupac: … 9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-ol …
HY10275
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Displaying drugs 2326 - 2350 of 3779 in total